These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196 [TBL] [Abstract][Full Text] [Related]
5. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan. Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641 [No Abstract] [Full Text] [Related]
6. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387 [TBL] [Abstract][Full Text] [Related]
7. Incorrect cost of infliximab in fistulizing Crohn's disease. Lichtenstein GR Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614 [No Abstract] [Full Text] [Related]
8. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. Catt H; Bodger K; Kirkham JJ; Hughes DA Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948 [TBL] [Abstract][Full Text] [Related]
9. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. de Groof EJ; Stevens TW; Eshuis EJ; Gardenbroek TJ; Bosmans JE; van Dongen JM; Mol B; Buskens CJ; Stokkers PCF; Hart A; D'Haens GR; Bemelman WA; Ponsioen CY; Gut; 2019 Oct; 68(10):1774-1780. PubMed ID: 31233395 [TBL] [Abstract][Full Text] [Related]
11. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of infliximab in Crohn's disease. Smart C; Selinger CP Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162 [TBL] [Abstract][Full Text] [Related]
13. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Negoescu DM; Enns EA; Swanhorst B; Baumgartner B; Campbell JP; Osterman MT; Papamichael K; Cheifetz AS; Vaughn BP Inflamm Bowel Dis; 2020 Jan; 26(1):103-111. PubMed ID: 31184366 [TBL] [Abstract][Full Text] [Related]
14. Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply. Bertani L; Fornai M; Antonioli L; Blandizzi C Aliment Pharmacol Ther; 2020 Sep; 52(6):1082. PubMed ID: 33119155 [No Abstract] [Full Text] [Related]
15. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD. Kay M; Wyllie R Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445 [No Abstract] [Full Text] [Related]
16. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy. Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Marchetti M; Liberato NL; Di Sabatino A; Corazza GR Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794 [TBL] [Abstract][Full Text] [Related]
18. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316 [TBL] [Abstract][Full Text] [Related]
19. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease. Mitton CR; Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479 [TBL] [Abstract][Full Text] [Related]
20. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use. Koelewijn C; Schrijvers A; Oldenburg B Neth J Med; 2006; 64(7):212-8. PubMed ID: 16929082 [No Abstract] [Full Text] [Related] [Next] [New Search]